Annexin A2 | Zendy

Xiang Fan | Zendy; Zhanyang Yu | Zendy; Jianxiang Liu | Zendy; Ning Liu | Zendy; Katherine A. Hajjar | Zendy; Karen L. Furie | Zendy; Eng H. Lo | Zendy; Xiaoying Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Annexin A2

Author(s) -

Xiang Fan,

Zhanyang Yu,

Jianxiang Liu,

Ning Liu,

Katherine A. Hajjar,

Karen L. Furie,

Eng H. Lo,

Xiaoying Wang

Publication year - 2010

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.110.596106

Subject(s) - medicine , tissue plasminogen activator , neurotoxicity , plasminogen activator , thrombolysis , recombinant tissue plasminogen activator , stroke (engine) , t plasminogen activator , fibrinolytic agent , pharmacology , ischemic stroke , toxicity , ischemia , mechanical engineering , myocardial infarction , modified rankin scale , engineering

Hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and the short treatment time window comprise major challenges for thrombolytic therapy. Improving tissue plasminogen activator therapy has become one of the highest priorities in the stroke field. Recent efforts have been aimed at identifying new strategies that might enhance the thrombolytic efficacy of tissue plasminogen activator at the same time as reducing its associated complications related to hemorrhage and neurotoxicity. We believe that the combination of low-dose tissue plasminogen activator with recombinant annexin A2 (a tissue plasminogen activator and plasminogen coreceptor) might constitute a promising approach. Our pilot study using a focal embolic stroke model in rats supports this hypothesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research